Apollomics Regains Compliance with Nasdaq Minimum Market Value Requirement

On July 13, 2026, Apollomics Inc. announced that it has regained compliance with the Nasdaq minimum Market Value of Listed Securities (MVLS) requirement for continued listing on the Nasdaq Capital Market. The company had previously received a deficiency notice from Nasdaq on June 18, 2026, after its MVLS fell below the required $35 million threshold for 30 consecutive business days. To resolve the matter, Apollomics was required to maintain an MVLS of at least $35 million for a minimum of 10 consecutive business days. Nasdaq's Listing Qualifications Staff determined that the company met this requirement during the period from June 23, 2026, to July 7, 2026. Consequently, Nasdaq issued a written notice on July 8, 2026, confirming that the company is back in compliance and the matter is officially closed. Apollomics is a late-stage clinical biopharmaceutical company focused on oncology, with its lead program, vebreltinib (APL-101), currently in Phase 2 clinical trials for non-small cell lung cancer and other advanced tumors.